FDA approves Astellas once-daily organ rejection drug PharmaTimes The thumbs-up is for the once-daily oral drug to be used with a regimen that includes treatment with with mycophenolate mofetil and corticosteroids, with or without basiliximab induction. Sef Kurstjens, chief medical officer at Astellas' US unit, said ... Astellas reports FDA approval of anti-rejection drug Astellas Pharma secures US FDA approval for ASTAGRAF XL |
